Breaking News Instant updates and real-time market news.

NVCR

Novocure

$79.04

-0.25 (-0.32%)

, RHHBY

Roche

$0.00

(0.00%)

04:55
09/17/19
09/17
04:55
09/17/19
04:55

American Society for Radiation Oncology to hold annual meeting

2019 ASTRO Annual Meeting will be held in Chicago on September 15-18.

NVCR

Novocure

$79.04

-0.25 (-0.32%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$43.60

-0.125 (-0.29%)

SIEGY

Siemens

$0.00

(0.00%)

TDY

Teledyne

$319.27

4.12 (1.31%)

VAR

Varian Medical

$117.21

-0.18 (-0.15%)

HTHIY

Hitachi

$0.00

(0.00%)

GHDX

Genomic Health

$71.45

-0.24 (-0.33%)

ESALY

Eisai

$0.00

(0.00%)

EKTAY

Elekta

$0.00

(0.00%)

BMY

Bristol-Myers

$49.47

0.07 (0.14%)

BSX

Boston Scientific

$41.96

0.15 (0.36%)

BAYRY

Bayer

$0.00

(0.00%)

AZN

AstraZeneca

$42.51

-0.25 (-0.58%)

ARAY

Accuray

$3.12

0.09 (2.97%)

MRK

Merck

$82.01

-0.6 (-0.73%)

MDT

Medtronic

$109.07

-0.56 (-0.51%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

HOLX

Hologic

$49.43

-0.29 (-0.58%)

ISR

IsoRay

$0.31

-0.005 (-1.58%)

  • 17

    Sep

  • 18

    Sep

  • 20

    Sep

  • 23

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 10

    Oct

  • 23

    Oct

  • 29

    Oct

  • 31

    Oct

  • 04

    Nov

  • 13

    Nov

NVCR Novocure
$79.04

-0.25 (-0.32%)

07/29/19
RHCO
07/29/19
UPGRADE
Target $105
RHCO
Buy
Novocure upgraded to Buy from Hold at SunTrust
SunTrust analyst Gregory Gilbert upgraded Novocure to Buy from Hold and raised his price target for the shares to $105 from $48.
07/29/19
07/29/19
UPGRADE
Target $105

Buy
Novocure upgraded to Buy from Hold at SunTrust
As previously reported, SunTrust analyst Gregory Gilbert upgraded Novocure to Buy from Hold and raised his price target for the shares to $105 from $48. The analyst says that he has long recognized the stock as an "under-the-radar" oncology investment story that calls for investor attention, but notes that the interest and excitement about Optune's potential in future indications is growing. Gilbert notes that his updated model now includes "probability adjusted" sales for Phase 3 indications with some areas of "potential conservatism".
07/26/19
WEDB
07/26/19
DOWNGRADE
Target $80
WEDB
Neutral
Novocure downgraded to Neutral from Outperform at Wedbush
Wedbush analyst David Nierengarten downgraded Novocure to Neutral from Outperform, telling he believes shares are now fully valued at the current levels following its recent performance. The analyst raised his price target to $80 from $57 to reflect current positive glioblastoma adoption trends, and notes that longer-term, positive results from clinical trials in new indications could give revenues a new growth trajectory beyond the underlying core GBM franchise. Nierengarten advises investors to wait for a more attractive entry point, as risks outweigh the rewards at these levels.
09/13/19
OPCO
09/13/19
NO CHANGE
Target $97
OPCO
Outperform
Novocure price target raised to $97 from $85 at Oppenheimer
Oppenheimer analyst Esther Rajavelu raised her price target for Novocure to $97 from $85 following investor meetings with CEO Asaf Danziger, CFO Wilco Groenhuysen and others. In a research note to investors, Rajavelu says she now better appreciates the incremental Optune GBM revenue potential if used in conjunction with radiation therapy and that while a registrational trial and regulatory approval will be required prior to use, she views this incremental patient pool as "low hanging" opportunity beginning in 2023. Rajavelu maintains an Outperform rating.
RHHBY Roche
$0.00

(0.00%)

07/23/19
JPMS
07/23/19
NO CHANGE
JPMS
Neutral
Competition questions for Biogen, Ions' Spinraza not dissipating soon, says JPMorgan
Following Biogen's (BIIB) quarterly results, JPMorgan analyst Jessica Fye notes that while there seems to be limited second quarter impact to the company's and partner Ions Pharmaceuticals' (IONS) Spinraza from Novartis' (NVS) Zolgensma international revenues were down quarter over quarter for a variety of reasons despite double-digit patient growth. Overall, the analyst maintains her view that Roche (RHHBY) and PTC Therapeutics' (PTCT) Risdiplam represents a key potential competitive threat to Spinraza given the convenience of oral dosing and with filing for Risdiplam anticipated in the second half of 2019, in addition to Zolgensma's launch, Fye does not see questions related to competition for Spinraza dissipating anytime soon. The analyst reiterates a Neutral rating on Ions Pharmaceuticals' shares.
07/23/19
BTIG
07/23/19
INITIATION
Target $46
BTIG
Buy
Adaptive Biotechnologies initiated with a Buy at BTIG
BTIG analyst Amanda Murphy initiated Adaptive Biotechnologies (ADPT) with a Buy rating and a price target of $46, saying the company's "clinical immunomics database" represents its "differentiating asset" and offers "incredible value" to biopharma companies. The analyst further cites Adaptive Biotechnologies' partnership with Roche (RHHBY) that should allow it to develop new diagnostics for early detection of diseases where antigens are unknown and also its "strategic" deal with Microsoft (MSFT), whose machine learning capabilities support its immune medicine platform.
09/13/19
DBAB
09/13/19
NO CHANGE
DBAB
Hold
Novartis' ofatumumab to be 'strong' competitor to Roche drug, says Deutsche Bank
Deutsche Bank analyst Richard Parkes tells investors in a research note after attending the ECTRIMS conference in Stockholm that data from Novartis' (NVS) ASCLEPIOS trials suggests ofatumumab will be a "strong" competitor for Roche's (RHHBY) Ocrevus in relapsing/remitting multiple sclerosis. Parkes says he expects physicians to view the drugs as having broadly comparable and highly compelling efficacy, with ofatumumab's at-home dosing an attractive option for some patients, suggesting meaningful upside potential to his current 2024E ofatumumab sales of $1.1B and possible risks to his forecasts for Roche's Ocrevus. According to physician feedback, Parkes says the drugs are likely to share a rapidly growing market. Parkes maintains a Hold rating and 90 CHF price target on Novartis shares.
07/26/19
UBSW
07/26/19
UPGRADE
UBSW
Buy
Roche upgraded to Buy from Neutral at UBS
UBS analyst Michael Leuchten upgraded Roche to Buy from Neutral and raised his price target for the shares to CHF 300 from CHF 270. The company's legacy portfolio, built around Herceptin and Rituxan, is showing greater resilience while its "credible" neuroscience pipeline is taking shape, Leuchten tells investors in a research note. As such, he now sees Roche's business model as less challenged.
SNY Sanofi
$43.60

-0.125 (-0.29%)

09/11/19
GABE
09/11/19
UPGRADE
GABE
Buy
Lexicon upgraded to Buy at Gabelli, says agreement a 'clean break'
Gabelli analyst Kevin Kedra upgraded Lexicon to Buy from Hold after the company said Sanofi (SNY) has finalized its termination of the sotagliflozin collaboration with a $260M payment, citing valuation and increased optimism for sotagliflozin's future. In a research note to investors, Kedra says the agreement is a "clean break" from Sanofi while also modestly extending Lexicon's cash runway, and expects Lexicon to have enough cash to support operations into 2021.
09/03/19
09/03/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Wayfair (W) initiated with a Buy at Goldman Sachs. 2. Square (SQ) initiated with an Underweight at Atlantic Equities. 3. InMode (INMD) initiated with an Outperform at Baird, an Overweight at Barclays, and a Buy at Canaccord and UBS. 4. Sanofi (SNY) initiated with an Outperform at Bernstein. 5. RealReal (REAL) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/03/19
BERN
09/03/19
INITIATION
Target $52
BERN
Outperform
Sanofi initiated with an Outperform at Bernstein
Bernstein analyst Wimal Kapadia initiated Sanofi with an Outperform and $52 price target.
09/11/19
SBSH
09/11/19
NO CHANGE
Target $3
SBSH
Buy
Lexicon settlement with Sanofi removes overhang, says Citi
Citi analyst Yigal Nochomovitz believes Lexicon Pharmaceuticals' (LXRX) settlement with Sanofi (SNY) removes an overhang and that the company's cash runway "may increase modestly." However, the funds are largely already spoken for with respect to continued funding of the core Phase 3 trials in n type 2 diabetes and the outcomes trials, Nochomovitz tells investors in a research note. The analyst keeps a Buy rating on Lexicon shares with a $3 price target.
SIEGY Siemens
$0.00

(0.00%)

07/15/19
UBSW
07/15/19
DOWNGRADE
Target $11.5
UBSW
Neutral
General Electric downgraded to Neutral from Buy at UBS
UBS analyst Damian Karas downgraded General Electric (GE) to Neutral and lowered his price target to $11.50 from $13, saying that a "notable" decline in interest rates and the continued weakness in the power market combine toward a "more balanced" upside with downside. The analyst states however that after the 20% relative year-to-date outperformance in the stock price, General Electric will continue its multi-year turnaround and transformation, with the Power segment becoming increasingly more important to investor sentiment given the concerns around China demand and Siemens' (SIEGY) intended listing of their Gas & Power unit.
07/23/19
SOCG
07/23/19
UPGRADE
SOCG
Buy
Siemens upgraded to Buy from Hold at Societe Generale
05/21/19
FBCO
05/21/19
UPGRADE
FBCO
Outperform
Siemens upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Andre Kukhnin upgraded Siemens to Outperform from Neutral and raised his price target for the shares to EUR 143 from EUR 115.
09/04/19
DBAB
09/04/19
UPGRADE
DBAB
Buy
Siemens upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Siemens to Buy from Hold with a price target of 105 euros.
TDY Teledyne
$319.27

4.12 (1.31%)

08/07/19
COWN
08/07/19
NO CHANGE
Target $300
COWN
Outperform
Teledyne price target raised to $300 from $275 at Cowen
Cowen analyst Joseph Giordano raised his price target on Teledyne to $300 from $275 citing its business diversity, idiosyncratic drivers, and upward earnings momentum. The analyst said it deserves its top pick status and yet remains widely underfollowed by the Street. Giordano reiterated his Outperform rating on Teledyne shares.
04/02/19
COWN
04/02/19
INITIATION
Target $265
COWN
Outperform
Teledyne initiated with an Outperform at Cowen
Cowen analyst Joseph Giordano initiated Teledyne with an Outperform and $265 price target citing its uniquely curated, diverse portfolio with secular leverage to high-end vision technologies, precision instrumentation, and modern warfare. Giordano sees nearly $2.5B in organic free cash flow generation over the next 5 years, supplementing a 1x net leveraged balance sheet.
07/25/19
NEED
07/25/19
NO CHANGE
Target $328
NEED
Buy
Teledyne price target raised to $328 from $275 at Needham
Needham analyst James Ricchiuti raised his price target on Teledyne to $328 and kept his Buy rating after its better than expected Q2 results driven by "much stronger" margins. The analyst cites the "ongoing strength" in the company's Life Sciences, Test & Measurement and Defense businesses, helping offset the weakness in its industrial machines segment. Ricchiuti further points to the bookings strength of Teledyne's Marine Instrumentation, highlighting the recovery in the offshore energy business expected later this year.
VAR Varian Medical
$117.21

-0.18 (-0.15%)

07/03/19
FBCO
07/03/19
NO CHANGE
Target $45
FBCO
Outperform
Sales of Boston Scientific's bead business not surprising, says Credit Suisse
Credit Suisse analyst Matt Miksic notes that Boston Scientific (BSX) has agreed to sell its portfolio of drug-loadable microspheres and "bland" embolic bead products for treating arteriovenous malformations and hyper vascular tumors to Varian (VAR) for $90M.The analyst does not view it as surprising, and reiterates an Outperform rating and $45 target on Boston Scientific's shares.
09/12/19
EVER
09/12/19
UPGRADE
EVER
In Line
Varian Medical upgraded to In Line from Underperform at Evercore ISI
07/17/19
PIPR
07/17/19
NO CHANGE
Target $15
PIPR
Overweight
Competitor recall highlights superiority of ViewRay system, says Piper Jaffray
After a notice appeared yesterday on the FDA website indicating that Elekta had issued a recall on its Unity system, Piper Jaffray analyst Matt O'Brien said he does not want to overstate the impact of this specific recall on ViewRay's (VRAY) ability to win business, but he does think that it highlights the superiority of the MRIdian system compared to Elekta's Unity platform. The analyst, who continues to believe that ViewRay's system is superior not only to Elekta in the MRgRT space but also when compared to "the dominant player," Varian Medical (VAR), keeps an Overweight rating and $15 price target on ViewRay shares.
09/12/19
EVER
09/12/19
UPGRADE
Target $123.5
EVER
In Line
Evercore upgrades Varian Medical to In Line on tariff relief from China
Evercore ISI analyst Vijay Kumar upgraded Varian Medical Systems to In Line from Underperform and raised his price target for the shares to $123.50 from $122. The analyst upgraded the shares after Varian received an exemption from China relative to the tariffs on imports from the U.S. The analyst thinks Varian's earnings were hurt by 3%-4% in fiscal 2019 from the tariffs, or 15c-20c per share. However, some of the upside from the tariff relief is offset by lower organic sales assumptions and currency volatility, Kumar tells investors in a research note.
HTHIY Hitachi
$0.00

(0.00%)

GHDX Genomic Health
$71.45

-0.24 (-0.33%)

07/30/19
LEHM
07/30/19
UPGRADE
Target $72
LEHM
Equal Weight
Genomic Health upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Jack Meehan upgraded Genomic Health (GHDX) to Equal Weight from Underweight and raised his price target for the shares to $72 from $45. The analyst believes the acquisition by Exact Sciences (EXAS) represents a good return for shareholders.
07/30/19
ADAM
07/30/19
DOWNGRADE
Target $72
ADAM
Hold
Genomic Health downgraded to Hold from Buy at Canaccord
Canaccord analyst Mark Massaro downgraded Genomic Health (GHDX) to Hold from Buy following its buyout offer from Exact Sciences for $2.8B or $72 per share. The analyst believes this will be the one and only bid, despite shares closing above the deal price. He does not expect any anti-trust concerns and expects the deal to close by the end of 2019. Massaro lowered his price target to the takeout price of $72 from $77 on Genomic Health shares.
07/30/19
ADAM
07/30/19
NO CHANGE
Target $135
ADAM
Buy
Exact Sciences Q2 results and deal a positive, says Canaccord
Canaccord analyst Mark Massaro said Exact Sciences (EXAS) delivered a major preannounced Q2 beat and raise as well as a $2.8B buyout offer for Genomic Health (GHDX). The analyst said he is positive on the deal and does not see the prospects for any competing bids despite the shares closing above the deal price of $72 per share. Massaro raised his price target to $135 from $125 on Exact Sciences shares.
07/30/19
NEED
07/30/19
DOWNGRADE
NEED
Hold
Genomic Health downgraded two notches to Hold from Strong Buy at Needham
Needham analyst Stephen Unger issued a double-downgrade of Genomic Health (GHDX) to Hold from Strong Buy after its decision to be acquired by Exact Sciences (EXAS) in a cash and stock deal. The analyst does not believe another buy will step in, with the transaction expected to be completed before the end of Q4.
ESALY Eisai
$0.00

(0.00%)

03/22/19
SBSH
03/22/19
DOWNGRADE
SBSH
Sell
Eisai downgraded to Sell from Neutral at Citi
Citi analyst Hidemaru Yamaguchi downgraded Eisai to Sell from Neutral.
08/05/19
SBSH
08/05/19
UPGRADE
SBSH
Neutral
Eisai upgraded to Neutral from Sell at Citi
Citi analyst Hidemaru Yamaguchi upgraded Eisai to Neutral from Sell.
03/21/19
COWN
03/21/19
NO CHANGE
Target $275
COWN
Outperform
Biogen price target cut to $275 from $400 at Cowen
Cowen analyst Philip Nadeau cut his price target for Biogen (BIIB) to $275 from $400 after the company and its partner Eisai (ESALY) announced that the Phase 3 ENGAGE and EMERGE studies of aducanumab for the treatment of cognitive impairment and dementia in Alzheimer's disease will be stopped for futility. The analyst maintains an Outperform rating.
03/22/19
NOMU
03/22/19
DOWNGRADE
NOMU
Reduce
Eisai downgraded to Reduce from Buy at Nomura Instinet
Nomura Instinet analyst Motoya Kohtani double downgraded Eisai to Reduce from Buy and lowered his price target for the shares to 6,000 yen from 17,000 yen following the cancellation of the Phase 3 trial of aducanumab. The analyst said he had high expectations for the drug.
EKTAY Elekta
$0.00

(0.00%)

07/16/19
JEFF
07/16/19
UPGRADE
JEFF
Hold
Elekta upgraded to Hold from Underperform at Jefferies
Jefferies analyst Kit Lee upgraded Elekta to Hold from Underperform with an increased price target of SEK126.
07/17/19
JEFF
07/17/19
NO CHANGE
JEFF
Elekta recall a positive for ViewRay, says Jefferies
Jefferies analyst Anthony Petrone noted that Elekta's (EKTAY) "Urgent Field Safety Notification" for its MR-Unity was officially classified as a Class 2 device recall by the FDA on Tuesday night. Petrone sees this recall potentially pushing orders towards ViewRay's (VRAY) MRIdian, increasing order flow into the back half of the year. The analyst maintained a Buy rating and $14 price target on ViewRay, and kept a Hold rating on Elekta.
BMY Bristol-Myers
$49.47

0.07 (0.14%)

08/27/19
RBCM
08/27/19
NO CHANGE
Target $206
RBCM
Sector Perform
Amgen price target raised to $206 from $192 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Amgen to $206, saying that despite the "sticker shock" of its $13.4B deal for the Otezla franchise, the transaction is expected to be immediately accretive to earnings and fitting well with its existing inflammation and immunology portfolio. The analyst believes that Amgen should be able to grow revenue "majorly" over the next 3 years as it leverages Otezla potential with its legal victory on Enbrel, stating that there is a case for its multiple to re-rate higher. MacKay keeps his Sector Perform rating on Amgen shares as he awaits for its emerging pipeline to also "fill the shoes" of its maturing assets.
08/19/19
MZHO
08/19/19
DOWNGRADE
MZHO
Neutral
Amgen, Celgene downgraded to Neutral on valuation at Mizuho
As previously reported, Mizuho analyst Salim Syed downgraded Amgen (AMGN) and Celgene (CELG), each to Neutral from Buy, "solely" on the stock's current trading prices nearing what the analyst views as appropriate valuations. Amgen has run up over the last week by about 10% following a "very clean Enbrel litigation win," but the stock price now gives full credit for its Enbrel IP, said Syed, who raised his price target on Amgen shares to $212 from $208. He also cut his price target on Celgene shares to $100 from $103, based on a calculation of one Bristol-Myers (BMY) share being worth $47, plus $50 cash per share and $3 for a risk-adjusted CVR valuation.
08/14/19
08/14/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Evercore Partners (EVR) upgraded to Neutral from Sell at Goldman Sachs with analyst Richard Ramsden saying believes that stronger U.S. large cap deal activity than he previously expected should support Evercore's revenues. 2. Sanofi (SNY) upgraded to Buy from Neutral at UBS with analyst Laura Sutcliffe saying she sees signs of a turnaround for the company and believes its pipeline can fixed ahead of patent expiration. 3. Bristol-Myers (BMY) upgraded to Overweight from Neutral at Atlantic Equities. 4. Horizon Pharma (HZNP) upgraded to Outperform from Market Perform at BMO Capital with analyst Gary Nachman citing the company's "strong" Q2 results driven by Krystexxa. 5. Ferrari (RACE) upgraded to Buy from Neutral at Goldman Sachs with analyst George Galliers citing the company's Q2 results earlier this month. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/14/19
ATLE
08/14/19
UPGRADE
Target $63
ATLE
Overweight
Bristol-Myers upgraded to Overweight from Neutral at Atlantic Equities
Atlantic Equities analyst Steve Chesney upgraded Bristol-Myers Squibb to Overweight from Neutral and raised his price target for the shares to $63 from $51.
BSX Boston Scientific
$41.96

0.15 (0.36%)

09/03/19
LEHM
09/03/19
INITIATION
Target $48
LEHM
Overweight
Boston Scientific reinstated with an Overweight at Barclays
Barclays analyst Kristen Stewart reinstated coverage of Boston Scientific with an Overweight rating and $48 price target. With multiple new products across all of its business units, the company is well positioned to sustain high-single digit organic sales growth for the foreseeable future, Stewart tells investors in a research note. She believes the consensus view on the stock "is the right view."
09/05/19
JPMS
09/05/19
INITIATION
Target $50
JPMS
Overweight
Boston Scientific reinstated with an Overweight at JPMorgan
JPMorgan analyst Robbie Marcus reinstated coverage of Boston Scientific with an Overweight rating and $50 price target following a period of restriction. The analyst continues to see the company as a "best-in-class Large-Cap MedTech asset," with "many shots on goal" to support a multi-year premium organic sales growth trajectory of 7%-10% through 2023.
09/05/19
09/05/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. General Electric (GE) initiated with an Equal Weight at Morgan Stanley. 2. Organigram (OGI) initiated with a Perform at Oppenheimer. 3. Wingstop (WING) initiated with a Market Perform at Raymond James. 4. Boston Scientific (BSX) reinstated with an Overweight at JPMorgan. 5. Cubic (CUB) initiated with a Hold at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/19
PIPR
08/07/19
NO CHANGE
PIPR
Piper says FDA update on paclitaxel-coated devices 'likely keeps the status quo'
After the FDA issued an update on its analysis of a late mortality signal in patients treated for peripheral artery disease in the femoropopliteal artery with paclitaxel-coated balloons and paclitaxel-eluting stents, Piper Jaffray analyst Matt O'Brien said the FDA's conclusion "likely keeps the status quo as far as usage in 2019." However, he still sees a significant patency benefit with these devices and expects further clinical data to resolve doctor's concerns in the longer-term, O'Brien stated. Makers of paclitaxel-coated devices include Boston Scientific (BSX) and Medtronic (MDT).
BAYRY Bayer
$0.00

(0.00%)

06/04/19
PIPR
06/04/19
NO CHANGE
Target $32
PIPR
Overweight
Piper remains buyer of Arvinas after 'transformative' Bayer alliance
Piper Jaffray analyst Edward Tenthoff views Arvinas' (ARVN) alliance with Bayer (BAYRY) as "transformative." He's a buyer of the stock ahead of the Phase I ARV-110 data in metastatic castrate resistance prostate cancer in the second half of 2019. The analyst estimates Arvinas now holds pro forma cash of $225M to fund operations into the second half of 2021. Tenthoff reiterates an Overweight rating on Bayer with a $32 price target.
07/10/19
WBLR
07/10/19
NO CHANGE
WBLR
Market Perform
Elanco combination with Bayer unlikely for many reasons, says William Blair
Shares of Elanco Animal Health (ELAN) have been unusually volatility over the past two days, William Blair analyst John Kreger tells investors in a research note. On Monday, the FDA approved a generic version of the company's largest product, Rumensin, and yesterday, the media reported speculation that Bayer (BAYRY) has approached Elanco about combining their animal health businesses, the analyst explains. He believes that while a negative development, the Rumensin generic had been expected and thus does not change his modeling assumptions. The Bayer speculation is more surprising but does not seem likely to happen "for a number of reasons," says Kreger. Elanco's largest challenge is bolstering its organic revenue growth, and buying a large company that is growing at a slower pace would only add to this challenge, according the analyst. Further, Elanco has committed to deleverage its balance sheet in the coming year, he adds. And lastly, Kreger believes there could be antitrust challenges from such a large combination. He keeps a Market Perform rating on Elanco shares.
08/15/19
UBSW
08/15/19
UPGRADE
Target $30
UBSW
Neutral
Elanco upgraded to Neutral from Sell at UBS
UBS analyst Navin Jacob upgraded Elanco Animal Health (ELAN) to Neutral from Sell with a price target of $30, down from $31. While the analyst still see risks to the company's fundamentals from African swine fever and generic Rumensin, he believes the shares are more fairly valued at current levels. Further, some of these headwinds may be offset by companion animal strength, Jacob tells investors in a research note. While concerns of a potential deal with Bayer (BAYRY) have pushed Elanco shares lower, "forecastable" concerns are built in at current levels, says the analyst.
08/26/19
BOFA
08/26/19
DOWNGRADE
Target $30
BOFA
Neutral
BofA/Merrill downgrades Elanco to Neutral on Bayer deal uncertainty
BofA/Merrill analyst Michael Ryskin downgraded Elanco Animal Health (ELAN) to Neutral from Buy with a $30 price target. While the acquisition of Bayer's (BAYRY) Animal Health business could turn out positive in the longer term, there is too much uncertainty in the near-term, including which parts of the portfolio will be divested due to antitrust issues, Ryskin tells investors in a research note. The analyst does not expect answers until nearer to deal close, which is expected in mid-2020.
AZN AstraZeneca
$42.51

-0.25 (-0.58%)

08/14/19
ARGS
08/14/19
NO CHANGE
Target $50
ARGS
Buy
AstraZeneca price target raised to $50 from $46 at Argus
Argus analyst John Eade raised his price target on AstraZeneca to $50 and kept his Buy rating, saying the stock has outperformed over the past quarter thanks to the pipeline developments that are returning the company to growth. The analyst notes that the company's future growth should be driven by its checkpoint inhibitor Imfinzi, and he sees the program tracking toward a billion-dollar blockbuster status from $338M reported in Q2. Eade further notes that AstraZeneca management has made efforts to address the ongoing pricing pressure and generic threats to its former blockbusters Nexium and Crestor by reducing costs and assembling a new drug pipeline.
08/13/19
BOFA
08/13/19
DOWNGRADE
Target $7
BOFA
Neutral
Clovis downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill Tazeen Ahmad downgraded Clovis (CLVS) to Neutral and lowered his price target to $7 from $13 after last week's release of positive topline results for its PARP inhibitor Lynparza to treat prostate cancer by the company's competitor AstraZeneca (AZN). The analyst notes that the Lynparza update alters his expectations in the prostate cancer market to assume a two-player landscape from day one, reducing his expectations for Clovis's Rubraca peak sales to $250M from $406M with peak U.S. BRCA penetration of 15%.
09/03/19
09/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Boston Beer (SAM) downgraded to Underperform from Hold at Jefferies with analyst Kevin Grundy saying his consumer survey and web scrapes point to the potential for greater competitive intensity in the "rapidly growing" spiked seltzer category. He views Boston Beer's valuation as "stretched" given its competitive risk in hard seltzers. 2. Spirit Airlines (SAVE) downgraded to Outperform from Strong Buy at Raymond James with analyst Savanthi Syth now expecting a delay in the inflection of sentiment to early 2020. 3. AstraZeneca (AZN) downgraded to Sell from Hold at DZ Bank. 4. Heico (HEI) downgraded to Sell from Neutral at UBS with analyst Louis Raffetto citing valuation. 5. Hilton (HLT) downgraded to Neutral from Outperform at Macquarie with analyst Chad Beynon saying he believes the stock's current valuation with near-peak EBITDA multiples prices in the positives while the company faces a lack of catalysts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/03/19
DZBN
09/03/19
DOWNGRADE
DZBN
Sell
AstraZeneca downgraded to Sell from Hold at DZ Bank
DZ Bank analyst Elmar Kraus downgraded AstraZeneca to Sell from Hold with a price target of 66 pounds.
ARAY Accuray
$3.12

0.09 (2.97%)

11/01/18
SBSH
11/01/18
UPGRADE
Target $3.9
SBSH
Neutral
Accuray upgraded to Neutral from Sell at Citi
Citi analyst Amit Hazan upgraded Accuray to Neutral and raised his price target for the shares to $3.90 from $3.50. The "long-anticipated" China quota announcement for the radiation therapy market came in well above expectations at 1,396 total systems, Hazan tells investors in a research note. He expects Accuray is now positioned to deliver above Street orders over the coming few years given its "prior success with Type A tenders in China last quota cycle." However, the analyst believes risks still remain in China around actual license award/allocation, new competition, and conversion of these orders into revenues.
09/16/19
09/16/19
NO CHANGE

Accuray to host investor meeting
Investor meeting to be held at ASTRO Annual Meeting 2019 in Chicago on September 16 at 4pm. Webcast Link
01/29/19
LSCM
01/29/19
NO CHANGE
Target $10
LSCM
Buy
Lake Street encourages investors to revisit Accuray shares
Lake Street analyst Brooks O'Neil expects the China joint venture Accuray announced yesterday to have a "significant competitive advantage by manufacturing innovative, locally branded and manufactured radiation therapy products." When combined with its revamped product line, strengthened commercial organization and improved balance sheet, Accuray is poised to deliver accelerating revenue growth and improved profitability over the next several years, O'Neil tells investors in a research note. The analyst encourages investors to "revisit this company now, while the stock continues to languish at a valuation that reflects the past, not the future of this revitalized company." He keeps a Buy rating on Accuray with a $10 price target.
MRK Merck
$82.01

-0.6 (-0.73%)

08/16/19
08/16/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Merck (MRK) initiated with an Outperform at SVB Leerink. 2. DocuSign (DOCU) initiated with a Buy at DA Davidson. 3. iQIYI (IQ) initiated with an Underweight at JPMorgan. 4. Goodyear Tire (GT) initiated with an Outperform at Exane BNP Paribas. 5. BlackBerry (BB) initiated with a Neutral at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/19
ARGS
08/07/19
NO CHANGE
Target $105
ARGS
Buy
Merck price target raised to $105 from $95 at Argus
Argus analyst David Toung raised his price target on Merck to $105 and kept his Buy rating after its "strong" Keytruda-driven Q2 earnings beat, also boosting his FY19 and FY20 EPS view by 16c and 10c to $4.89 and $5.35 respectively. The analyst sees Merck's "blockbuster" Keytruda drug on track for additional indications in the U.S., Japan, China and Europe, with additional growth drivers coming from its Gardasil, Bridion, Lynparza, and Lenvima programs.
08/15/19
LEER
08/15/19
INITIATION
Target $103
LEER
Outperform
Merck initiated with an Outperform at SVB Leerink
SVB Leerink analyst Daina Graybosch initiated Merck with an Outperform rating and $103 price target.
07/22/19
OPCO
07/22/19
DOWNGRADE
OPCO
Perform
Oppenheimer downgrades Intec Pharma after 'major setback' of trial miss
As previously reported, Oppenheimer analyst Jay Olson downgraded Intec Pharma (NTEC) to Perform from Outperform after the company announced "a major setback" as the ACCORDANCE study did not achieve statistical superiority to Sinemet on the primary endpoint of reduction in daily OFF time. He noted that the company still has additional opportunities with other drugs, including proprietary partnerships with Novartis (NVS) and Merck (MRK), but said the read across from AP-CD/LD to other AP applications in different diseases is uncertain following this morning's news.
MDT Medtronic
$109.07

-0.56 (-0.51%)

08/21/19
LEHM
08/21/19
NO CHANGE
Target $117
LEHM
Overweight
Medtronic price target raised to $117 from $110 at Barclays
Barclays analyst Kristen Stewart said Medtronic "started this year off on the right note" and she raised her price target on the stock to $117 from $110 to reflect a higher target multiple, more confidence on its pipeline and an increased calendar year 2020 earnings estimate. She keeps an Overweight rating on Medtronic shares, adding that "investors should have a great opportunity to 'kick the tires' with three investor briefings planned" over the next month.
08/21/19
BMOC
08/21/19
NO CHANGE
Target $118
BMOC
Outperform
Medtronic price target raised to $118 from $107 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Medtronic to $118 and kept her Outperform rating after its above-consensus Q1 results, saying the company appears to finally be positioned to "string together" a series of "consistent good quarters". The analyst adds that Medtronic outperformed in Q1 despite the difficult annual comp and prior to many of its pipeline products starting to gain traction. Wuensh further notes that the company is beginning to see the benefits of cost controls put in place last year as its operating margins expanded by 90bps.
09/03/19
NEED
09/03/19
INITIATION
Target $43
NEED
Buy
Axonics initiated with a Buy at Needham
Needham analyst Mike Matson initiated Axonics (AXNX) with a Buy rating and a price target of $43, citing the company's pending entry into the "large and growing" sacral neuromodulation market and thereby ending the "monopoly" held by Medtronic (MDT) by offering a superior product. The analyst further believes that Axonics' commercial organization and strategy should allow it to capture market share and drive "significant" revenue growth and operating leverage, while warning that Medtronic's competitive response may be "too little, too late."
09/16/19
JPMS
09/16/19
NO CHANGE
JPMS
Overweight
Medtronic one of the few that could see multiple expansion, says JPMorgan
JPMorgan analyst Robbie Marcus believes Medtronic's pipeline is "deep and often overlooked." He sees a number of "significant potential catalysts" over the coming year that he believes many investors aren't focused on. The analyst thinks investors will want to own Medtronic not only for the expected sales acceleration, from ~4% this fiscal year to ~5% in fiscal 2021, but also for the potential upside in the out-years as pipeline catalysts, that "aren't appropriately modeled by the Street," play out. Medtronic is one of the few large-cap names that could see further multiple expansion, says Marcus, who reiterates an Overweight rating on the shares.
WTKWY Wolters Kluwer
$0.00

(0.00%)

05/17/19
JPMS
05/17/19
DOWNGRADE
JPMS
Underweight
Wolters Kluwer downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Daniel Kerven downgraded Wolters Kluwer to Underweight from Neutral with a price target of 57 euros.
HOLX Hologic
$49.43

-0.29 (-0.58%)

08/01/19
PIPR
08/01/19
NO CHANGE
Target $59
PIPR
Overweight
Hologic price target raised to $59 from $49 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Hologic to $59 from $49 citing the company's "strong" fiscal Q3 results. He believes Hologic's guidance is conservative and leaves room for a beat in Q4. The company is seeing continued momentum in Diagnostics and Breast Health, says the analyst, who reiterates an Overweight rating on the shares.
04/24/19
PIPR
04/24/19
NO CHANGE
Target $49
PIPR
Overweight
Hologic checks suggest worsening Cynosure trends, says Piper Jaffray
Piper Jaffray analyst William Quirk says his eBay (EBAY) channel checks suggest Hologic's (HOLX) positive trends in his earlier research have reversed with more used Cynosure lasers hitting third party websites and prices trending down. While Cynosure represents just ~10% of Hologic's total revenue, it carries a "heavy psychological burden on the share price," Quirk tells investors in a research note. He maintains an Overweight rating on Hologic with a $49 price target, but recognizes the company's March quarter results may bring a better entry point if his checks prove accurate.
07/10/19
PIPR
07/10/19
NO CHANGE
Target $49
PIPR
Overweight
Hologic still trades at 'substantial discount' to peers, say Piper Jaffray
Piper Jaffray analyst William Quirk says his CynoSure checks are "mixed" with available lasers increasing on eBay and several other third party websites, but with "stable higher value" SculpSure systems and increasing laser prices. This business line is showing more signs of stabilization, Quirk tells investors in a research note. He believes Hologic's core Breast Health and Diagnostics businesses will again have the largest incremental impact on potential upside in the quarter. The company's shares continue to trade at a "substantial discount" to peers, says Quirk, who keeps an Overweight rating on the name with a $49 price target.
08/14/19
ARGS
08/14/19
NO CHANGE
Target $62
ARGS
Buy
Hologic price target raised to $62 from $56 at Argus
Argus analyst David Toung raised his price target on Hologic to $62 and kept his Buy rating after its Q3 earnings beat and "strong" revenue growth that were partially offset by the currency headwinds. The analyst notes that the company's Breast Health and Molecular Diagnostics businesses delivered "strong growth" while it also continued to expand its presence in overseas markets. Toung further anticipates continued solid execution, new product launches, and the integration of recent acquisitions driving "strong performance" in the second half of 2019.
ISR IsoRay
$0.31

-0.005 (-1.58%)

02/13/19
HCWC
02/13/19
NO CHANGE
HCWC
H.C. Wainwright reiterates Buy on IsoRay after Q2 results
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and 70c price target on IsoRay following the company's Q2 results, which slightly beat the firm's estimate on revenue and was in-line on net loss per share. The analyst noted that double digit revenue growth continued for the seventh consecutive quarter and believes "the current strong momentum of revenue growth could be sustained by upcoming full launches of Blu Build and GammaTile." Ramakanth also believes the company's $7.9M in cash and cash equivalents should be sufficient to fund it into Q2 of FY20.
11/09/18
MAXM
11/09/18
DOWNGRADE
MAXM
Hold
IsoRay downgraded to Hold from Buy at Maxim
01/28/19
HCWC
01/28/19
INITIATION
Target $0.7
HCWC
Buy
IsoRay assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of IsoRay with a Buy rating and 70c price target. The company is at an inflection point of sustainable revenue growth, Ramakanth tells investors in a research note. He views the company as as a turnaround story.
11/09/18
MAXM
11/09/18
DOWNGRADE
MAXM
Hold
IsoRay downgraded to Hold from Buy at Maxim
As reported earlier, Maxim analyst Jason McCarthy downgraded IsoRay to Hold from Buy after its Q4 results saw a sequential decline of 2.5%. The analyst maintains his view that the company's "Cs-131 is a superior isotope for radio-therapy", but also notes that it continues to struggle to drive revenue growth. McCarthy adds that it is too early to tell whether its GammaTile be the answer, but only sees incremental revenue growth from the program.

TODAY'S FREE FLY STORIES

AMGN

Amgen

$200.76

2.05 (1.03%)

09:15
10/14/19
10/14
09:15
10/14/19
09:15
Initiation
Amgen initiated  »

Amgen resumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

JAZZ

Jazz Pharmaceuticals

$118.61

0.62 (0.53%)

09:13
10/14/19
10/14
09:13
10/14/19
09:13
Initiation
Jazz Pharmaceuticals initiated  »

Jazz Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBI

Pitney Bowes

$4.40

0.04 (0.92%)

09:13
10/14/19
10/14
09:13
10/14/19
09:13
Hot Stocks
Pitney Bowes issues statement on malware attack »

Pitney Bowes issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

INFY

Infosys

$10.97

-0.22 (-1.97%)

09:13
10/14/19
10/14
09:13
10/14/19
09:13
Downgrade
Infosys rating change  »

Infosys downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

ARGO

Argo Group

$67.34

1.4 (2.12%)

09:12
10/14/19
10/14
09:12
10/14/19
09:12
Hot Stocks
Argo Group holder Voce comments on SEC probe »

Voce Capital, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARW

Arrow Electronics

$74.22

1.095 (1.50%)

, TXN

Texas Instruments

$130.08

2.52 (1.98%)

09:11
10/14/19
10/14
09:11
10/14/19
09:11
Recommendations
Arrow Electronics, Texas Instruments analyst commentary  »

Longbow says Arrow…

ARW

Arrow Electronics

$74.22

1.095 (1.50%)

TXN

Texas Instruments

$130.08

2.52 (1.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

BKI

Black Knight

$61.68

0.39 (0.64%)

09:11
10/14/19
10/14
09:11
10/14/19
09:11
Hot Stocks
Black Knight receives to patents from USPTO »

Black Knight announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

UPS

UPS

$116.06

0.76 (0.66%)

09:10
10/14/19
10/14
09:10
10/14/19
09:10
Hot Stocks
UPS launches Storage on Demand service »

UPS announced the launch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

HON

Honeywell

$163.52

2.63 (1.63%)

09:09
10/14/19
10/14
09:09
10/14/19
09:09
Hot Stocks
Honeywell finalizing new T55 engine to power U.S. Army's Chinook helicopters »

Honeywell is finalizing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

OKTA

Okta

$116.19

1.65 (1.44%)

, PING

Ping Identity

$16.47

0.45 (2.81%)

09:09
10/14/19
10/14
09:09
10/14/19
09:09
Initiation
Okta, Ping Identity, Zscaler, Crowdstrike initiated  »

Citi expands Software…

OKTA

Okta

$116.19

1.65 (1.44%)

PING

Ping Identity

$16.47

0.45 (2.81%)

ZS

Zscaler

$48.16

0.81 (1.71%)

CRWD

Crowdstrike

$60.24

-1.08 (-1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 19

    Nov

  • 12

    Dec

  • 16

    Dec

ERIC

Ericsson

$8.44

0.2 (2.43%)

09:09
10/14/19
10/14
09:09
10/14/19
09:09
Hot Stocks
Ericsson and Watch Communications enter into partnership »

Watch Communications has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

OSTK

Overstock.com

$10.67

-0.18 (-1.66%)

09:08
10/14/19
10/14
09:08
10/14/19
09:08
Hot Stocks
Medici Land Governance signs MOU with St. Kitts and Nevis government »

Overstock.com announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMTL

Comtech

$31.24

0.51 (1.66%)

09:08
10/14/19
10/14
09:08
10/14/19
09:08
Hot Stocks
Comtech awarded $4.4M contract renewal »

Comtech announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RETA

Reata Pharmaceuticals

$95.80

9.86 (11.47%)

09:08
10/14/19
10/14
09:08
10/14/19
09:08
Recommendations
Reata Pharmaceuticals analyst commentary  »

Reata Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$20.76

0.76 (3.80%)

09:06
10/14/19
10/14
09:06
10/14/19
09:06
Recommendations
Wendy's analyst commentary  »

Wendy's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

  • 13

    Nov

LAND

Gladstone Land

$11.87

(0.00%)

09:06
10/14/19
10/14
09:06
10/14/19
09:06
Hot Stocks
Gladstone Land clarifies certain aspects of external fee structure »

Gladstone Land offered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

LMAT

LeMaitre

$31.29

-0.03 (-0.10%)

09:06
10/14/19
10/14
09:06
10/14/19
09:06
Hot Stocks
Admedus sells CardioCel, VascuCel patch business to LeMaitre for $A36.2M »

Admedus announces the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HUBS

HubSpot

$163.05

2.975 (1.86%)

09:05
10/14/19
10/14
09:05
10/14/19
09:05
Recommendations
HubSpot analyst commentary  »

Enterprise, sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

GWPH

GW Pharmaceuticals

$114.35

-3.8 (-3.22%)

09:04
10/14/19
10/14
09:04
10/14/19
09:04
Recommendations
GW Pharmaceuticals analyst commentary  »

Investor concerns related…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 05

    Nov

LAND

Gladstone Land

$11.87

(0.00%)

09:04
10/14/19
10/14
09:04
10/14/19
09:04
Hot Stocks
Gladstone Land says 'hopeful' China plan will make 'Midwest growers stronger' »

Gladstone Land…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

LMAT

LeMaitre

$31.29

-0.03 (-0.10%)

09:03
10/14/19
10/14
09:03
10/14/19
09:03
Hot Stocks
Breaking Hot Stocks news story on LeMaitre »

Admedus sells CardioCel,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ABT

Abbott

$79.61

0.11 (0.14%)

09:02
10/14/19
10/14
09:02
10/14/19
09:02
Hot Stocks
Abbott and Omada Health announce partnership »

Abbott and Omada Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

XGN

Exagen

$12.18

-1.17 (-8.76%)

09:00
10/14/19
10/14
09:00
10/14/19
09:00
Initiation
Exagen initiated  »

Exagen initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOOP

Loop Industries

$10.39

0.01 (0.10%)

08:56
10/14/19
10/14
08:56
10/14/19
08:56
Initiation
Loop Industries initiated  »

Loop Industries initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

Jeld-Wen

$16.08

-2.56 (-13.73%)

08:55
10/14/19
10/14
08:55
10/14/19
08:55
Recommendations
Jeld-Wen analyst commentary  »

Jeld-Wen price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.